Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rocaglamide SCHEMBL29439568 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL751061 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL10054686 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL20386162 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL29407815 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocaglamide SCHEMBL24127774 | 1.00 | EIF4A1 (1.00) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL12182311 | 0.93 | EIF4A1 (0.87) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL29370550 | 0.91 | EIF4A1 (0.84) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL15079078 | 0.91 | EIF4A1 (0.86) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| Rocagloic Acid SCHEMBL750035 | 0.91 | EIF4A1 (0.86) | EIF4A1NFKB1RELACYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119351519-A | Anti-cryptosporidium small molecule lead compound for targeting cryptosporidium helicase | 吉林大学 | 2025-01-24 | — | — | CN | claimed |
| US-20230201245-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | CZ BIOHUB SF, LLC | 2023-06-29 | — | — | US | claimed |
| EP-4161646-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTION | Chan Zuckerberg Biohub, Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| EP-4126016-A1 | AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES | Fred Hutchinson Cancer Center (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022047234-A1 | DRUG COMBINATION KITS AND METHODS OF DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | WO | claimed |
| US-20180169123-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | UNIV HEIDELBERG RUPRECHT KARLS (DE) | 2018-06-21 | — | — | US | claimed |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-10-06 | — | — | US | claimed |
| US-20260115213-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250345307-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3866780-B1 | FLAVAGLINE DERIVATIVES FOR INHIBITION OF KRAS ONCOGENE ACTIVATION | SJP BIOTEC GMBH (CH) | 2025-11-12 | — | — | EP | disclosed |
| US-12403121-B2 | Anticancer rocaglamide derivatives | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025092976-A1 | PROTEIN TRANSLATION INHIBITOR | 映恩生物制药（苏州）有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119351519-A | Anti-cryptosporidium small molecule lead compound for targeting cryptosporidium helicase | 吉林大学 | 2025-01-24 | — | — | CN | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011140334-A2 | COMPOUNDS, METHODS OF MAKING OR IDENTIFYING COMPOUNDS, AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | TRUSTEES OF BOSTON UNIVERSITY | 2011-03-17 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | disclosed |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | LU ZHIMIN | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403121-B2 | Anticancer rocaglamide derivatives | HRH3, HRH2, CYTH3 | EIF4A1 3984/4885NFKB1 3629/4885RELA 2369/4885 |
| US-20260115213-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | SARS1, RNGTT, NSUN3 | EIF4A1 56/4885NFKB1 3327/4885RELA 1553/4885 |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885NFKB1 2/4885RELA 5/4885 |
| US-20090082371-A1 | Treatment of Viral Disease and Cancer With Nf-kappaB Inhibitors | RELA, NFKBIA, NFKB1 | EIF4A1 894/4885NFKB1 3/4885RELA 1/4885 |
| US-20250345307-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | SARS1, RNGTT, ACE2 | EIF4A1 180/4885NFKB1 3731/4885RELA 2277/4885 |
| US-20160287553-A1 | TRANSLATION INHIBITORS IN HIGH-DOSE CHEMO- AND/OR HIGH-DOSE RADIOTHERAPY | EIF4E, EIF4EBP1, EIF5B | EIF4A1 14/4885NFKB1 353/4885RELA 112/4885 |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | NFKBIA, NFE2L2, NFKB1 | EIF4A1 4015/4885NFKB1 3/4885RELA 12/4885 |
| US-20180169123-A1 | COMBINATION THERAPY WITH A FLAVAGLINE AND 2-DEOXYGLUCOSE | SLC5A2, SLC5A1, G6PD | EIF4A1 2074/4885NFKB1 2824/4885RELA 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.